{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T22:39:00Z","timestamp":1762814340459,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.idc.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T15:53:07Z","timestamp":1712591587000},"page":"295-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary Tract Infection Treatment"],"prefix":"10.1016","volume":"38","author":[{"given":"Arsheena","family":"Yassin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanaya","family":"Bhowmick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.idc.2024.03.007_bib1","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases society of america and the european society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2024.03.007_bib3","unstructured":"Cortes-Penfield N. Session: Spoiler alert! preview of clinical practice guideline updates. In: Complicated Urinary Tract Infection; ID Week 2023."},{"issue":"7","key":"10.1016\/j.idc.2024.03.007_bib7","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1128\/AAC.00405-16","article-title":"Antimicrobial activities of ceftazidime-avibactam and comparator agents against gram-negative organisms isolated from patients with urinary tract infections in U.S. medical centers, 2012 to 2014","volume":"60","author":"Sader","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2024.03.007_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2024.03.007_bib10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QCO.0000000000000751","article-title":"Antimicrobial-resistant bacteria in international travelers","volume":"34","author":"Sridhar","year":"2021","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2024.03.007_bib11","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Clinical practice. uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2024.03.007_bib12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00228-013-1520-x","article-title":"Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care","volume":"69","author":"Geerts","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.idc.2024.03.007_bib13","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/jac\/dkv147","article-title":"Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials","volume":"70","author":"Huttner","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"sup1","key":"10.1016\/j.idc.2024.03.007_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/1120009X.2017.1380357","article-title":"Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections","volume":"29","author":"Novelli","year":"2017","journal-title":"J\u00a0Chemother Florence Italy"},{"author":"Bactrim","key":"10.1016\/j.idc.2024.03.007_bib15"},{"issue":"20","key":"10.1016\/j.idc.2024.03.007_bib16","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2024.03.007_bib18","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2024.03.007_bib20","first-page":"ciad357","article-title":"Antibiotic myths for the infectious diseases clinician","volume":"13","author":"McCreary","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2024.03.007_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.0954-6820.1983.tb03690.x","article-title":"Three-day treatment of acute lower urinary tract infections in women. A double-blind study with amoxycillin and co-trimazine","volume":"213","author":"Sigurdsson","year":"1983","journal-title":"Acta Med Scand"},{"issue":"3","key":"10.1016\/j.idc.2024.03.007_bib24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/clinids\/12.3.458","article-title":"Short-term treatment of uncomplicated lower urinary tract infections in women","volume":"12","author":"Norrby","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2024.03.007_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/AAC.47.3.897-900.2003","article-title":"Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women","volume":"47","author":"Kavatha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"10.1016\/j.idc.2024.03.007_bib26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/ajhp\/zxac068","article-title":"Aminopenicillins for treatment of ampicillin-resistant enterococcal urinary tract infections","volume":"79","author":"Bunnell","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.idc.2024.03.007_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijantimicag.2017.06.008","article-title":"Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience","volume":"51","author":"Shah","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.idc.2024.03.007_bib33","first-page":"021655","article-title":"A\u00a0systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2024.03.007_bib34","first-page":"2307","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2024.03.007_bib36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2024.03.007_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120970743","article-title":"Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus","volume":"8","author":"Pontefract","year":"2020","journal-title":"SAGE Open Med"},{"issue":"4","key":"10.1016\/j.idc.2024.03.007_bib38","first-page":"175","article-title":"Linezolid for the Treatment of urinary tract infections caused by vancomycin-resistant enterococci","volume":"9","author":"Wingler","year":"2021","journal-title":"Pharm J Pharm Educ Pract"},{"issue":"6","key":"10.1016\/j.idc.2024.03.007_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.idc.0000144898.12957.eb","article-title":"Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria","volume":"12","author":"Naber","year":"2004","journal-title":"Infect Dis Clin Pract"},{"issue":"4","key":"10.1016\/j.idc.2024.03.007_bib40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ckj\/sfs076","article-title":"Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient","volume":"5","author":"Eden","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.idc.2024.03.007_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2490-13-33","article-title":"Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series","volume":"13","author":"Ramaswamy","year":"2013","journal-title":"BMC Urol"},{"issue":"5","key":"10.1016\/j.idc.2024.03.007_bib42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijantimicag.2008.11.003","article-title":"Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections","volume":"33","author":"Fisher","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.idc.2024.03.007_bib43","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine escherichia coli isolates from adult and adolescent females in the united states from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2024.03.007_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12879-021-05842-0","article-title":"Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study","volume":"21","author":"Zilberberg","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2024.03.007_bib45","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.idc.2024.03.007_bib46","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","volume":"18","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2024.03.007_bib47","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"author":"Mandell","key":"10.1016\/j.idc.2024.03.007_bib48"},{"issue":"4","key":"10.1016\/j.idc.2024.03.007_bib49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.22.4.672","article-title":"Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid","volume":"22","author":"Iravani","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2024.03.007_bib50","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.28.5.693","article-title":"Randomized comparative study of amoxicillin-clavulanic acid and co-trimoxazole in the treatment of acute urinary tract infections in adults","volume":"28","author":"Karachalios","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2024.03.007_bib51","doi-asserted-by":"crossref","first-page":"e9392581","DOI":"10.12659\/AOT.939258","article-title":"Breaking antimicrobial resistance: high-dose amoxicillin with clavulanic acid for urinary tract infections due to extended-spectrum beta-lactamase (ESBL)-producing klebsiella pneumoniae","volume":"28","author":"Wilkowski","year":"2023","journal-title":"Ann Transplant"},{"issue":"2","key":"10.1016\/j.idc.2024.03.007_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1179\/joc.1996.8.2.122","article-title":"Piperacillin\/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial","volume":"8","author":"Sifuentes-Osornio","year":"1996","journal-title":"J\u00a0Chemother Florence Italy"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2024.03.007_bib53","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/BF01745250","article-title":"Piperacillin\/tazobactam in complicated urinary tract infections","volume":"20","author":"Now\u00e9","year":"1994","journal-title":"Intensive Care Med"},{"issue":"9","key":"10.1016\/j.idc.2024.03.007_bib56","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.46.9.2895-2900.2002","article-title":"Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study","volume":"46","author":"Tomera","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2024.03.007_bib57","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jac\/dkq152","article-title":"Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms","volume":"65","author":"Bazaz","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2024.03.007_bib59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinids\/21.1.86","article-title":"A\u00a0multicenter comparative study of meropenem and imipenem\/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients","volume":"21","author":"Cox","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2024.03.007_bib60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/17512433.2015.1090874","article-title":"Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections","volume":"8","author":"Mawal","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.idc.2024.03.007_bib61","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in\u00a0vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"9981","key":"10.1016\/j.idc.2024.03.007_bib62","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.idc.2024.03.007_bib68","doi-asserted-by":"crossref","first-page":"e0271221","DOI":"10.1128\/spectrum.02712-21","article-title":"In\u00a0vitro activity of cefiderocol against U.S. and European gram-negative clinical isolates collected in 2020 as part of the sentry antimicrobial surveillance program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"9","key":"10.1016\/j.idc.2024.03.007_bib75","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552024000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552024000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T22:36:46Z","timestamp":1762814206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552024000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0891552024000096"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2024.03.007","relation":{},"ISSN":["0891-5520"],"issn-type":[{"type":"print","value":"0891-5520"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary Tract Infection Treatment","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}